Literature DB >> 18061001

Drug therapy for atrial fibrillation.

Simone Musco1, Emily L Conway, Peter R Kowey.   

Abstract

Atrial fibrillation (AF) is the most frequently diagnosed arrhythmia. Prevalence increases with age, and the overall incidence is expected to increase as the population continues to age. Choice of pharmacologic therapy for atrial fibrillation depends on whether or not the goal of treatment is maintaining sinus rhythm or tolerating atrial fibrillation with adequate control of ventricular rates. New antiarrhythmic drugs are being tested in clinical trials. Drugs that target remodeling and inflammation are being tested for their use as prevention of AF or as adjunctive therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18061001     DOI: 10.1016/j.mcna.2007.08.002

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  3 in total

Review 1.  Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.

Authors:  Sean T Duggan; Lesley J Scott
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 2.  Pleiotropic effects of statins in atrial fibrillation patients: the evidence.

Authors:  Hadi Ar Hadi; Wael Al Mahmeed; Jassim Al Suwaidi; Samer Ellahham
Journal:  Vasc Health Risk Manag       Date:  2009-06-29

Review 3.  Dronedarone.

Authors:  Sheridan M Hoy; Susan J Keam
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.